Healthcare technology company Apiject Holdings Inc announced on Friday that it has signed a lease for a 30,000-square-foot pharmaceutical manufacturing facility in Apex, North Carolina.

The new facility is planned to house two advanced Blow-Fill-Seal (BFS) production lines and operate as an FDA-registered 503B outsourcing facility focused on producing essential generic injectable medicines currently on the FDA's drug shortage list. The site will also serve as the corporate headquarters of Vanguard Utility, Apiject's operational subsidiary.

Apiject recently filed a New Drug Application (NDA) in the United States for its first BFS-based prefilled injection device.

Jay Walker, Apiject chairman, said: "America's dependence on foreign sources for essential medicines is a strategic vulnerability. Reshoring critical manufacturing -- from energy and rare earth minerals to pharmaceuticals -- is a national priority. This facility represents the next step in Apiject's ongoing work to translate advanced American manufacturing technology into real domestic capacity."